Disc Medicine (IRON) Stock Price, News & Analysis

Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $59.47 to $60.83
• 50-Day Range: $45.12 to $60.94
• 52-Week Range: $30.82 to $68.73
• Volume: 224,396 shs
• Average Volume: 378,410 shs
• Market Capitalization: $2.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $95.73
• Consensus Rating: Buy

Disc Medicine Stock Analysis - MarketRank™

Disc Medicine scored higher than 67% of companies evaluated by MarketBeat, and ranked 351st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Disc Medicine has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Disc Medicine has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.

Price to Book Value per Share Ratio

Disc Medicine has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.58% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Disc Medicine has recently decreased by 4.06%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Disc Medicine does not currently pay a dividend.

Dividend Growth

Disc Medicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.58% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Disc Medicine has recently decreased by 4.06%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.67

News Sentiment

Disc Medicine has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Disc Medicine this week, compared to 6 articles on an average week.

Search Interest

7 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

2 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,797,556.00 in company stock.

Percentage Held by Insiders

Only 4.24% of the stock of Disc Medicine is held by insiders.

Percentage Held by Institutions

83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IRON Stock Analysis - Frequently Asked Questions

How have IRON shares performed this year?

Disc Medicine's stock was trading at $63.40 on January 1st, 2025. Since then, IRON stock has decreased by 4.4% and is now trading at $60.61.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) announced its earnings results on Wednesday, May, 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by $0.03.

Who are Disc Medicine's major shareholders?

Disc Medicine's top institutional shareholders include Aberdeen Group plc (0.09%), Atle Fund Management AB (0.07%), KLP Kapitalforvaltning AS (0.01%) and Mirae Asset Global Investments Co. Ltd.. Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Kevin Bitterman, Mona Ashiya, John D Quisel, Pamela Stephenson, Jean M Franchi, William Jacob Savage, Jonathan Yen-Wen Yu, Rahul Khara, Brian Richard Macdonald, Joanne Bryce and William Richard White.
View institutional ownership trends.

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Disc Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/25/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IRON
• CIK: 1816736
• Web: www.discmedicine.com
• Phone: 617-401-4400
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Disc Medicine: $95.73
• High Price Target: $132.00
• Low Price Target: $75.00
• Potential Upside/Downside: +57.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$109.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -22.61%
• Return on Assets: -21.07%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 37.65
• Quick Ratio: 37.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.85 per share
• Price / Book: 4.08

Miscellaneous

• Outstanding Shares: 34,630,000
• Free Float: 33,166,000
• Market Cap: $2.10 billion
• Optionable: Not Optionable
• Beta: 0.76